AUGUST 2024LIFE SCIENCES REVIEW 19CXO INSIGHTSWhat are the primary challenges in the life sciences sector? How is innovation in technology addressing these challenges effectively?The life science industry presents tremendous opportunities to address major health concerns that have previously remained unaddressed. It is evident that technological advancements are shaping the field with a notable trend toward precision medicine. This approach entails developing drugs or biomarkers that specifically target the underlying condition of the disease, offering targeted treatment and potentially minimizing side effects for patients. Recently, there has been a proliferation of various technologies and modalities designed to tackle specific types of diseases, from traditional small molecules and biologics to protein therapies, monoclonal antibodies, and gene therapy. These diverse approaches have already shown promising results across different disease areas. However, amid these advancements, one pressing challenge is the escalating competition as more companies seek similar patient populations while performing clinical trials.Another major challenge is related to funding. The industry has become substantially more challenging compared to just a couple of years ago in securing capital due to rising interest rates, geopolitical uncertainties, and long-term prospects. While companies with promising drugs and clinical data may still attract finances by raising substantial capital, this has led to industry consolidation and the closure of some companies that are unable to secure adequate funding.Simultaneously, market access also poses a significant hurdle. For instance, while the US remains a market that embraces innovation, it has become more challenging due to payer-imposed hurdles aimed at cost control. The situation in Europe is more severe, with countries facing deficits and tough choices regarding public policy priorities and financing.What strategic measures are you implementing to proactively mitigate potential challenges associated with biosimilars?Our primary focus lies in the development of highly differentiated drugs that offer distinct advantages over existing competition and provide cost-saving benefits for payers as compared to traditional treatments.At Abivax, our current phase 3 program for ulcerative colitis is simplifying drug administration with once-daily oral dosing. However, the most remarkable aspect of our drug, obefazimod, is the outcome observed Marc de Garidel, Chief Executive Officer, AbivaxLEVERAGING TECHNOLOGICAL ADVANCEMENTS FOR DEVELOPING INNOVATIVE THERAPEUTICSIn an interview with Life Sciences Review Europe, Marc de Garidel, Chief Executive Officer at Abivax, sheds light on implementing emerging technologies to increase access to lifesaving medications at potentially lower costs.Marc de Garidel
< Page 9 | Page 11 >